Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis

Journal of Immunology

Volumn 193, Issue 10, 2014, Pages 5044-5055

  Luo, Jie ^a   Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CYTRX VACCINE; FREUND ADJUVANT; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; TITERMAX VACCINE; UNCLASSIFIED DRUG; AUTOANTIBODY; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BINDING SITE; CLINICAL FEATURE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; NEUROTRANSMISSION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; SEQUENCE HOMOLOGY; ADMINISTRATION AND DOSAGE; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENE REARRANGEMENT; HUMAN; IMMUNOLOGY; LEWIS RAT; MUSCLE; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PATHOLOGY; PROTEIN SUBUNIT; SUBCUTANEOUS DRUG ADMINISTRATION; TORPEDO;

ANIMALS; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MUSCLES; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PROTEIN SUBUNITS; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RECOMBINANT PROTEINS; TORPEDO; VACCINES;

EID: 84910156515     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401392     Document Type: Article

References (47)

1. Berrih-Aknin, S., and R. Le Panse. 2014. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J. Autoimmun. 52: 90-100
2. Keesey, J. C. 2004. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29: 484-505
3. Phillips, L. H. 2004. The epidemiology of myasthenia gravis. Semin. Neurol. 24: 17-20
4. Conti-Fine, B. M., M. Milani, and H. J. Kaminski. 2006. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116: 2843-2854
5. Lindstrom, J. M. 2000. Acetylcholine receptors and myasthenia. Muscle Nerve 23: 453-477
6. Luo, J., P. Taylor, M. Losen, M. H. de Baets, G. D. Shelton, and J. Lindstrom. 2009. Main immunogenic region structure promotes binding of conformationdependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J. Neurosci. 29: 13898-13908
7. Lennon, V. A., J. M. Lindstrom, and M. E. Seybold. 1975. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141: 1365-1375
8. Lindstrom, J. M., B. L. Einarson, V. A. Lennon, and M. E. Seybold. 1976. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis. J. Exp. Med. 144: 726-738
9. Luo, J., and J. Lindstrom. 2012. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. Autoimmunity 45: 245-252
10. Gomez, A. M., N. Willcox, P. C. Molenaar, W. Buurman, P. Martinez-Martinez, M. H. De Baets, and M. Losen. 2012. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann. N. Y. Acad. Sci. 1274: 48-59
11. Gold, R., M. C. Dalakas, and K. V. Toyka. 2003. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol. 2: 22-32
12. Steinman, L., J. T. Merrill, I. B. McInnes, and M. Peakman. 2012. Optimization of current and future therapy for autoimmune diseases. Nat. Med. 18: 59-65
13. Wekerle, H., and R. Hohlfeld. 2010. Zero tolerance (to acetylcholine receptor) and ways to overcome it. Ann. Neurol. 67: 422-424
14. Xiao, B. G., and H. Link. 1997. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin. Immunol. Immunopathol. 85: 119-128
15. Lennon, V. A., E. H. Lambert, K. R. Leiby, T. B. Okarma, and S. Talib. 1991. Recombinant human acetylcholine receptor a-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146: 2245-2248
16. Im, S. H., D. Barchan, M. C. Souroujon, and S. Fuchs. 2000. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol. 165: 3599-3605
17. Yi, H. J., C. S. Chae, J. S. So, S. J. Tzartos, M. C. Souroujon, S. Fuchs, and S. H. Im. 2008. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor. Mol. Immunol. 46: 192-201
18. Dalakas, M. C. 2013. Novel future therapeutic options in myasthenia gravis. Autoimmun. Rev. 12: 936-941
19. Luo, J., A. Kuryatov, and J. M. Lindstrom. 2010. Specific immunotherapy of experimental myasthenia gravis by a novel mechanism. Ann. Neurol. 67: 441-451
20. Lindstrom, J. M., V. A. Lennon, M. E. Seybold, and S. Whittingham. 1976. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann. N. Y. Acad. Sci. 274: 254-274
21. Lennon, V. A., J. M. Lindstrom, and M. E. Seybold. 1976. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann. N. Y. Acad. Sci. 274: 283-299
22. Lindstrom, J. 1996. Neuronal nicotinic acetylcholine receptors. Ion Channels 4: 377-450
23. Mamalaki, A., N. Trakas, and S. J. Tzartos. 1993. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur. J. Immunol. 23: 1839-1845
24. Medgyesi, G. A., K. Mikló s, J. Kulics, G. Füst, J. Gergely, and H. Bazin. 1981. Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system. Immunology 43: 171-176
25. Gomez, A. M., K. Vrolix, P. Martínez-Martínez, P. C. Molenaar, M. Phernambucq, E. Van der Esch, H. Duimel, F. Verheyen, R. E. Voll, R. A. Manz, et al. 2011. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J. Immunol. 186: 2503-2513
26. Jang, E., W. S. Cho, M. L. Cho, H. J. Park, H. J. Oh, S. M. Kang, D. J. Paik, and J. Youn. 2011. Foxp3+ regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells. J. Immunol. 186: 1546-1553
27. Xiang, Z., A. J. Cutler, R. J. Brownlie, K. Fairfax, K. E. Lawlor, E. Severinson, E. U. Walker, R. A. Manz, D. M. Tarlinton, and K. G. Smith. 2007. FcgRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8: 419-429
28. Drachman, D. B., R. N. Adams, R. Hu, R. J. Jones, and R. A. Brodsky. 2008. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann. N. Y. Acad. Sci. 1132: 305-314
29. Dixon, F. J., H. Jacot-Guillarmod, and P. J. McConahey. 1967. The effect of passively administered antibody on antibody synthesis. J. Exp. Med. 125: 1119-1135
30. Brinc, D., G. A. Denomme, and A. H. Lazarus. 2009. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? Curr. Opin. Hematol. 16: 488-496
31. Heyman, B. 2000. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18: 709-737
32. Na, D., D. Kim, and D. Lee. 2006. Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice. J. Theor. Biol. 241: 830-851
33. Cribbs, D. H., A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, D. Babikyan, P. Kesslak, T. Kieber-Emmons, C. W. Cotman, and M. G. Agadjanyan. 2003. AdjuVant-dependent modulation of Th1 and Th2 responses to immunization with b-amyloid. Int. Immunol. 15: 505-514
34. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383: 787-793
35. Rødgaard, A., F. C. Nielsen, R. Djurup, F. Somnier, and S. Gammeltoft. 1987. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin. Exp. Immunol. 67: 82-88
36. Loutrari, H., A. Kokla, and S. J. Tzartos. 1992. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur. J. Immunol. 22: 2449-2452
37. Tüzün, E., R. Huda, and P. Christadoss. 2011. Complement and cytokine based therapeutic strategies in myasthenia gravis. J. Autoimmun. 37: 136-143
38. Lindstrom, J. M., M. E. Seybold, V. A. Lennon, S. Whittingham, and D. D. Duane. 1976. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059
39. Sanders, D. B., T. M. Burns, G. R. Cutter, J. M. Massey, V. C. Juel, and L. Hobson-Webb, Muscle Study Group. 2014. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 49: 483-486
40. Maiti, P. K., T. Feferman, S. H. Im, M. C. Souroujon, and S. Fuchs. 2004. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152: 112-120
41. McGuirk, P., and K. H. Mills. 2002. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol. 23: 450-455
42. Faria, A. M., and H. L.Weiner. 2006. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13: 143-157
43. Cousens, L. P., Y. Su, E. McClaine, X. Li, F. Terry, R. Smith, J. Lee, W. Martin, D. W. Scott, and A. S. De Groot. 2013. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 2013: 621693
44. Marrack, P., A. S. McKee, and M. W. Munks. 2009. Towards an understanding of the adjuVant action of aluminium. Nat. Rev. Immunol. 9: 287-293
45. Hughes, E. G., X. Peng, A. J. Gleichman, M. Lai, L. Zhou, R. Tsou, T. D. Parsons, D. R. Lynch, J. Dalmau, and R. J. Balice-Gordon. 2010. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 30: 5866-5875
46. Sine, S. M. 2012. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol. Rev. 92: 1189-1234
47. Tzartos, S. J., M. E. Seybold, and J. M. Lindstrom. 1982. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 79: 188-192.